CA
NZ
UK
AU
IND
US
…
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
PolyPid Ltd (NASDAQ: PYPD) is a clinical-stage specialty biopharmaceutical company focused on developing localized drug-delivery platforms for infectious and inflammatory conditions; public disclosures describe a technology intended to prolong local drug exposure and reduce systemic toxicity. Long-term growth may be driven by successful clinical trial outcomes, regulatory approvals, and licensing or partnership deals for its delivery platform, which could support adoption in areas of unmet medical need and enable multiple clinical programs.
Key risks are clinical and regulatory failure, need for ongoing financing that may dilute shareholders, and competitive or technological obsolescence.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -39.43M | -42.33M | -36.87M | -6.91M | 5.92M |
| Net income | -39.52M | -40.71M | -35.32M | 4.75M | 5.92M |
| Selling general administrative | 8.01M | 9.48M | 7.70M | 4.48M | 5.26M |
| Selling and marketing expenses | 2.89M | 2.97M | 1.61M | - | 0.55M |
| Reconciled depreciation | 1.72M | 1.12M | 1.01M | 0.95M | 0.41M |
| Ebit | -40.61M | -43.99M | -27.28M | -18.56M | -42.56M |
| Ebitda | -38.89M | -42.88M | -26.27M | -29.22M | -42.15M |
| Depreciation and amortization | 1.72M | 1.12M | 1.01M | -10.66M | 0.41M |
| Operating income | -38.89M | -42.88M | -26.27M | -18.56M | -18.36M |
| Other operating expenses | 38.89M | 42.88M | 26.27M | 18.56M | 18.36M |
| Interest expense | 1.02M | 87.14M | 0.02M | 0.01M | 0.04M |
| Tax provision | 0.10M | - | - | - | - |
| Interest income | 0.27M | 0.47M | 0.47M | 0.06M | 0.13M |
| Net interest income | -0.54M | 0.54M | -10.60M | 0.04M | 0.08M |
| Income tax expense | 0.10M | -1.62M | -1.54M | -11.65M | -24.28M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 38.89M | 42.88M | 26.27M | 18.56M | 18.36M |
| Total other income expense net | -0.54M | 0.54M | -10.60M | 11.65M | 24.20M |
| Net income from continuing ops | -39.52M | -42.33M | -36.87M | -6.91M | 5.92M |
| Net income applicable to common shares | -39.56M | -42.33M | -42.92M | -13.33M | 0.09M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 15.37M | 25.97M | 44.23M | 75.85M | 33.77M |
| Other current assets | 0.46M | 1.09M | 24.99M | 2.58M | 0.75M |
| Total liab | 17.47M | 20.11M | 8.01M | 3.07M | 2.83M |
| Total stockholder equity | -2.10M | 5.86M | 36.23M | 72.78M | 30.93M |
| Other current liab | 1.97M | -0.03M | 3.40M | 1.66M | 1.00M |
| Common stock | - | - | - | - | 0.13M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -238.31M | -214.41M | -174.62M | -132.29M | -93.30M |
| Other liab | - | 2.84M | 0.20M | 0.19M | 0.25M |
| Other assets | - | 0.10M | 0.66M | 22.76M | 0.23M |
| Cash | 5.61M | 8.55M | 9.82M | 4.32M | 3.94M |
| Total current liabilities | 7.29M | 8.64M | 7.81M | 2.88M | 2.58M |
| Current deferred revenue | - | 2.55M | 0.27M | 0.24M | - |
| Net debt | 6.17M | 5.18M | -9.82M | -4.32M | -3.94M |
| Short term debt | 4.54M | 4.98M | - | - | - |
| Short long term debt | 4.00M | 4.02M | - | - | - |
| Short long term debt total | 11.78M | 13.73M | - | - | - |
| Other stockholder equity | 236.21M | 220.27M | 210.85M | 205.06M | 124.24M |
| Property plant equipment | - | 11.68M | 8.76M | 5.89M | 6.12M |
| Total current assets | 6.07M | 14.19M | 34.81M | 47.59M | 27.41M |
| Net tangible assets | - | 5.83M | 36.23M | 72.78M | -87.63M |
| Short term investments | 0.00M | 4.04M | 22.38M | 40.16M | 22.68M |
| Net receivables | - | 0.30M | 0.12M | 0.14M | 0.04M |
| Long term debt | 6.38M | 7.57M | - | - | - |
| Inventory | - | 0.21M | -22.50M | - | - |
| Accounts payable | 0.77M | 1.14M | 4.14M | 0.97M | 1.58M |
| Accumulated other comprehensive income | - | - | - | -3.14M | -2.12M |
| Non currrent assets other | 0.09M | 0.10M | 0.66M | 22.36M | 0.23M |
| Non current assets total | 9.30M | 11.78M | 9.42M | 28.25M | 6.35M |
| Capital lease obligations | 1.40M | 2.13M | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 16.57M | 39.89M | -40.77M | -23.56M | 10.96M |
| Change to liabilities | -0.55M | 2.22M | -0.61M | 0.45M | -0.89M |
| Total cashflows from investing activities | 16.57M | 36.90M | -40.77M | -23.56M | 10.96M |
| Net borrowings | 11.31M | 11.31M | 11.31M | 11.31M | - |
| Total cash from financing activities | 16.43M | 1.03M | 62.77M | 37.65M | 9.39M |
| Change to operating activities | -0.53M | 2.13M | 0.83M | -1.53M | 1.05M |
| Net income | -39.56M | -42.60M | -36.87M | -6.91M | 5.92M |
| Change in cash | -1.31M | 5.55M | 0.41M | -3.27M | 3.67M |
| Begin period cash flow | 10.46M | 4.91M | 4.50M | 7.77M | 4.10M |
| End period cash flow | 9.14M | 10.46M | 4.91M | 4.50M | 7.77M |
| Total cash from operating activities | -34.32M | -32.39M | -21.60M | -17.36M | -16.68M |
| Issuance of capital stock | 4.42M | 0.00M | 62.76M | 37.65M | 9.36M |
| Depreciation | 1.72M | 1.12M | 1.01M | 0.95M | 0.41M |
| Other cashflows from investing activities | - | - | -22.12M | -22.12M | -22.12M |
| Change to account receivables | - | - | -1.92M | 0.07M | 0.31M |
| Sale purchase of stock | - | - | - | 37.65M | 9.39M |
| Other cashflows from financing activities | 12.41M | 1.03M | 0.02M | -23.56M | 9.39M |
| Change to netincome | 4.60M | 4.75M | 15.95M | -10.39M | -23.48M |
| Capital expenditures | 1.77M | 2.99M | 1.18M | 0.88M | 3.07M |
| Change in working capital | -1.08M | 4.35M | -1.69M | -1.01M | 0.47M |
| Stock based compensation | 4.31M | 4.75M | 4.58M | 0.98M | 0.99M |
| Other non cash items | 0.29M | -0.27M | 11.37M | -11.37M | -24.47M |
| Free cash flow | -36.08M | -35.38M | -22.77M | -18.24M | -19.75M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| PYPD PolyPid |
-0.12 1.92% |
6.12 | - | - | - | 9.20 | -1.40 |
| NVO Novo Nordisk A/S |
-0.79 1.90% |
40.59 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-1.97 0.36% |
548.90 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-9.49 1.03% |
910.47 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
| Name | Title | Year Born |
|---|---|---|
| Ms. Dikla Czaczkes Akselbrad | Chief Exec. Officer | 1973 |
| Ms. Dalit Hazan | Exec. VP of R&D and Clinical & Regulatory Affairs | 1971 |
| Mr. Ori Warshavsky | Chief Operating Officer - US | 1978 |
| Mr. Jonny Missulawin | Sr. VP of Fin. | NA |
| Evgeny Valdman | Exec. VP of Operations | NA |
| Mr. Tal Vilnai | Gen. Counsel & Corp. Sec. | NA |
| Ms. Rivi Lev-ari | VP of Human Resource | NA |
| Dr. Jean-Marc Hagai Pharm.D. | Chief Commercial Officer | NA |
| Ms. Dikla Czaczkes Akselbrad | CEO & Director | 1973 |
| Mr. Jonny Missulawin | Chief Financial Officer | 1987 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.70%
Communication Services
-0.44%
Consumer Cyclical
-0.50%
Consumer Defensive
+0.08%
Energy
-0.07%
Financial Services
-0.35%
Financials
-2.20%
Healthcare
-0.95%
Industrials
-0.37%
Real Estate
-0.38%
Technology
-1.52%
Utilities
-0.57%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...